NEWS

Advancements in Patient-Centered Care

Stay up to date with the latest advancements in oral oncolytics, medically-integrated oncology, and cancer care best practices.

Stemline Therapeutics, a subsidiary of Menarini Group, Receives U.S. FDA Approval for ORSERDU™ (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer

January 31, 2023 | Katie Edmiston

                        ESR1 mutations are present in up to 40% of ER+, HER2- advanced or metastatic breast cancers. ESR1 mutations are a known driver of resistance to standard endocrine therapy, and so far, have been difficult to treat. ORSERDU is the first endocrine innovation in more than 20 years, […]
read more

Co-pay Accumulator Reform – HELP Copays Act (H.R. 5801)

January 26, 2023 | Katie Edmiston

FOR IMMEDIATE RELEASE January 26, 2023 Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 kevin.scorsone@ncoda.org www.ncoda.org Earlier this year, NCODA and the Patient Access Network (PAN) Foundation co-authored a letter to the United States House of Representatives focused on co-pay accumulator reform through the HELP Copays Act (H.R. 5801). PAN and […]
read more

NCODA Launches Two New Multi-Specialty Medically Integrated Pharmacy Accreditation Programs

January 20, 2023 | Katie Edmiston

FOR IMMEDIATE RELEASE January 20, 2023 MEDIA CONTACT: Katie Edmiston Katie.Edmiston@ncoda.org 813-843-1629 CAZENOVIA, NY – NCODA is pleased to announce two new Center of Excellence (CoE) Medically Integrated Pharmacy (MIP) accreditation offerings: 1) Multi-specialty and 2) Multi-specialty with Oncology Focus.  Multi-specialty Accreditation is designed for MIPs servicing multiple specialty disease states, and Multi-specialty Accreditation with […]
read more

NCODA APPOINTS NEW MEMBERS TO EXECUTIVE COUNCIL

January 12, 2023 | Katie Edmiston

  FOR IMMEDIATE RELEASE January 12, 2023 MEDIA CONTACT: Katie Edmiston Katie.Edmiston@ncoda.org 813-843-1629   CAZENOVIA, NY – NCODA, a non-profit organization whose Mission is to empower the medically-integrated oncology team to deliver positive, patient-centered outcomes – announces the appointment of three new members to its executive council: William Mitchell, MD, Lance Ortega, MBA, BSN, RN, […]
read more

New NCODA Accredited Residency Program Provides Comprehensive Experience in Medically-Integrated Oncology Pharmacy

December 21, 2022 | Katie Edmiston

FOR IMMEDIATE RELEASE December 21, 2022 MEDIA CONTACT: Katie Edmiston Katie.Edmiston@ncoda.org 813-843-1629   CAZENOVIA, NY – NCODA, Inc. is excited to announce the creation of a new and innovative Accredited Medically-Integrated Oncology Pharmacy (MIOP) Residency Program. NCODA worked with cancer centers throughout the United States to provide the program framework and accreditation for this unique […]
read more

STATEMENT FROM NCODA LEGISLATIVE & POLICY ADVISORY COMMITTEE

December 16, 2022 | Katie Edmiston

FOR IMMEDIATE RELEASE December 16, 2022 Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org www.ncoda.org In a year that has seen plenty of legislative and political uncertainty, NCODA is proud of the Legislative & Policy Advisory Committee (LPAC) for maintaining their steadfast goal to educate our membership and shed […]
read more

Mirati Therapeutics Announces U.S. FDA Accelerated Approval of KRAZATI™ (adagrasib) as a Targeted Treatment Option for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

December 14, 2022 | Katie Edmiston

12/12/2022 SAN DIEGO, Dec. 12, 2022 /PRNewswire/ — Mirati Therapeutics, Inc. (NASDAQ: MRTX), a targeted oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for KRAZATI™ (adagrasib), a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received […]
read more

New NCODA Program Equips Oncology Pharmacy Technicians with Premier Certification

December 8, 2022 | Katie Edmiston

FOR IMMEDIATE RELEASE December 8, 2022 MEDIA CONTACT: Katie Edmiston Katie.Edmiston@ncoda.org 813-843-1629   CAZENOVIA, NY – The need for oncology-focused pharmacy technician training has increased exponentially with advancements in the oral oncolytic landscape. To empower the entire medically-integrated oncology team and ensure an advanced level of patient care, NCODA’s Oncology Pharmacy Technician Association (OPTA) has […]
read more

Libtayo® (cemiplimab-rwlc) in Combination with Chemotherapy Approved by the FDA as First-line Treatment for Advanced Non-small Cell Lung Cancer (NSCLC)

November 14, 2022 | Katie Edmiston

Approval based on superior survival outcomes of Libtayo plus chemotherapy, compared to chemotherapy alone, in a patient population with a wide range of disease characteristics Second advanced NSCLC indication expands patient population eligible for a Libtayo-based regimen to include combination treatment with chemotherapy  irrespective of PD-L1 expression levels TARRYTOWN, N.Y., Nov. 8, 2022 /PRNewswire/ — Regeneron Pharmaceuticals, […]
read more

U.S. FDA Approves TECVAYLI™ (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

November 1, 2022 | Katie Edmiston

TECVAYLI™, an off-the-shelf, subcutaneous therapy, is an important new medicine for patients with incurable blood cancer who face limited treatment options HORSHAM, Pa., October 25, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved TECVAYLI™ (teclistamab-cqyv) for the treatment of adult patients with relapsed […]
read more

NYOH Leads Rally In Response to Life Threatening Policy Change That Effects Cancer Patients

October 13, 2022 | Katie Edmiston

Cazenovia, NY (Oct 13, 2022) – With a recent policy change made to The New York State Department of Health’s (NYSDOH) Medicaid Pharmacy Program that prevents patients from obtaining their oral medication through their physician dispensary, practice leaders from New York Oncology Hematology (NYOH) immediately took action and led efforts to bring attention to this […]
read more

Children with Chronic Graft Versus Host Disease (cGVHD) May Now Be Prescribed IMBRUVICA® (ibrutinib)

October 3, 2022 | Katie Edmiston

The U.S. Food and Drug Administration approved the use of IMBRUVICA for the treatment of pediatric patients one year and older with cGVHD after failure of one or more lines of systemic therapy This is the first approved treatment option for children with cGVHD under 12 years of age and the only Bruton’s tyrosine kinase […]
read more

BIDEN MOONSHOT INITIATIVE FOCUSED ON CHANGING CANCER LANDSCAPE

September 13, 2022 | Katie Edmiston

FOR IMMEDIATE RELEASE September 13, 2022 STATEMENT FROM NCODA LEGISLATIVE & POLICY ADVISORY COMMITTEE Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org www.ncoda.org On the afternoon of Monday, September 12, President Biden arrived in Boston and made his way to the John F. Kennedy (JFK) Presidential Library. His visit […]
read more

Incyte Announces FDA Approval of Pemazyre® (pemigatinib) as the First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms (MLNs) with FGFR1 Rearrangement

September 12, 2022 | Katie Edmiston

Incyte Announces FDA Approval of Pemazyre® (pemigatinib) as the First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms (MLNs) with FGFR1 Rearrangement August 26, 2022 – This marks the second indication for Pemazyre, which received accelerated FDA approval in 2020 for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor […]
read more

SpringWorks Therapeutics Announces Data from Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Progressing Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2022

September 12, 2022 | Katie Edmiston

SpringWorks Therapeutics Announces Data from Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Progressing Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2022 – Nirogacestat Treatment Resulted in Rapid, Sustained and Statistically Significant Improvements in Primary and All Key Secondary Efficacy Endpoints – – NDA Submission to the U.S. FDA […]
read more

MAINE CONTINUES REFORM FOR PATIENTS

September 6, 2022 | Katie Edmiston

FOR IMMEDIATE RELEASE September 6, 2022 STATEMENT FROM NCODA LEGISLATIVE & POLICY ADVISORY COMMITTEE Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org www.ncoda.org In two consecutive legislative sessions in 2021 and 2022, the state of Maine has focused on reform for patients battling cancer. The legislative bodies in Maine […]
read more

Children with Chronic Graft Versus Host Disease (cGVHD) May Now Be Prescribed IMBRUVICA® (ibrutinib)

August 26, 2022 | Katie Edmiston

New Approval Alert  The U.S. Food and Drug Administration approved the use of IMBRUVICA® (ibrutinib) for the treatment of pediatric patient one year and older with cGvHD after failure of one or more lines of systemic therapy. Official statement HERE.  
read more

Defining Appropriate Quality Performance Metrics for Pharmacies Dispensing Oral Oncology Therapies

August 19, 2022 | Katie Edmiston

NCODA applauds the recent published article in the American Journal of Managed Care® by our members at Florida Cancer Specialists and Research Institute titled “Defining Appropriate Quality Performance Metrics for Pharmacies Dispensing Oral Oncology Therapies.” Click the link below to read this article: https://www.ajmc.com/view/defining-appropriate-quality-performance-metrics-for-pharmacies-dispensing-oral-oncology-therapies  
read more

NCODA and Florida Cancer Specialists & Research Institute Announce New Oncology Stakeholder Education Exchange Program

August 16, 2022 | Katie Edmiston

Cazenovia, NY, August 16, 2022 –  New cancer treatment therapies, technologies and innovations continue to be discovered and approved for use at a rapid pace, creating an education challenge for physicians and other healthcare professionals within the complex oncology landscape. Working collaboratively with Florida Cancer Specialists & Research Institute, LLC (FCS), NCODA, Inc. developed a […]
read more

Cazenovia nonprofit to host ‘Passion Fore Patients’ Golf Tournament

August 9, 2022 | Katie Edmiston

Cazenovia nonprofit to host ‘Passion Fore Patients’ Golf Tournament
read more

Financial Impact of Medically Integrated Pharmacy Interventions on Oral Oncolytic Prescriptions

August 2, 2022 | Katie Edmiston

The NCODA CAWT Tool was recently published in the Journal of Clinical Oncology – Oncology Practice. The article highlights the medication waste associated with external specialty pharmacies compared to Medically Integrated Pharmacies (MIPs), as well as increased cost avoidance demonstrated by MIP teams. As the utilization of oral cancer medications rises, it is vital that cancer centers track costs associated with […]
read more

NCODA Announces New Education Platform for the Medically-Integrated Oncology Community

July 27, 2022 | Katie Edmiston

NCODA University Offers Complimentary Accredited Learning Through Virtual and In-Person Events CAZENOVIA, NY, July 27, 2022 – Empowering all stakeholders in oncology with easily accessible, patient-centered education and collaborative learning opportunities is fundamental to NCODA, Inc. Today, NCODA, launches NCODA University, a new division of the organization, which will allow medically-integrated oncology professionals to obtain […]
read more

Florida Takes Action Against Prescription Drug Pricing

July 14, 2022 | Katie Edmiston

FOR IMMEDIATE RELEASE July 14, 2022 STATEMENT FROM NCODA LEGISLATIVE & POLICY ADVISORY COMMITTEE Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org www.ncoda.org Florida Takes Action Against Prescription Drug Pricing   NCODA is proud to share that on July 8, 2022, Florida Governor Ron DeSantis issued Executive Order 22-164 […]
read more

Three Oncology Leaders Join NCODA Executive Council

July 7, 2022 | Katie Edmiston

FOR IMMEDIATE RELEASE July 7, 2022 MEDIA CONTACT: Katie Edmiston Katie.Edmiston@ncoda.org 813-843-1629 CAZENOVIA, NY – NCODA is pleased to announce the appointment of three oncology leaders to the Executive Council: Meg Butler, PharmD (Clearview Cancer Institute), Gury Doshi, MD (Texas Oncology), and Xylina Gregg, MD (Utah Cancer Specialists). “Our Executive Council is comprised of a […]
read more

NCODA International Abstract Published in Croatian Journal of Oncology

July 5, 2022 | Katie Edmiston

NCODA recently published an abstract titled “The NCODA PQI: Educating Your Medically Integrated Team While Supporting Better Patient Care with a Concise, Peer-Reviewed,Pharmacy-Led Resource” in the Croatian Journal of Oncology. This abstract is based on a presentation that our Founder & Executive Director, Michael Reff, RPh, MBA, delivered at the Croatian Virtual Congress of Oncology Pharmacy. Click HERE […]
read more

NCODA’s Legislative & Policy Advisory Committee Adds Top Thought Leaders in Oncology

June 30, 2022 | Katie Edmiston

FOR IMMEDIATE RELEASE June 30, 2022 STATEMENT FROM NCODA LEGISLATIVE & POLICY ADVISORY COMMITTEE Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org www.ncoda.org   NCODA Legislative & Policy Advisory Committee Adds Top Thought Leaders in Oncology NCODA is pleased to announce that Debra Patt, MD, PhD, MBA, Executive Vice […]
read more

RECENTLY PUBLISHED: ASCO/NCODA Standards Show Positive Benefit in Community Pharmacy

June 16, 2022 | Katie Edmiston

NCODA members from a community pharmacy in Canada recently published an article in the Journal of Oncology Pharmacy Practice that aimed to characterize their alignment with the ASCO/NCODA Standards and describe its impact on CDK4/6i treatment use. The authors concluded that a structured, patient-centered pharmacy practice model integrating the ASCO/NCODA Standards ensures timely medication refills, close monitoring, and allows […]
read more

OKLAHOMA RECOGNIZES PHARMACISTS AS ESSENTIAL COMMUNITY PROVIDERS

June 10, 2022 | Katie Edmiston

FOR IMMEDIATE RELEASE STATEMENT FROM NCODA LEGISLATIVE & POLICY ADVISORY COMMITTEE Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org www.ncoda.org        OKLAHOMA RECOGNIZES PHARMACISTS AS ESSENTIAL COMMUNITY PROVIDERS NCODA applauds the recent efforts of the Oklahoma Legislature that passed HB 2322. This law recognizes pharmacists as Essential Community Providers […]
read more

NCODA Announces New Legislative & Policy Advisory Committee (LPAC) Member, Barbara McAneny, MD, FASCO, MACP

June 2, 2022 | Katie Edmiston

NCODA is proud to announce that Barbara McAneny, MD, FASCO, MACP will be joining our Legislative & Policy Advisory Committee (LPAC). Dr. McAneny is the CEO of New Mexico Oncology Hematology Consultants. Dr. McAneny was also elected by the American Medical Association House of Delegates and served as AMA President from 2018 – 2019. “NCODA […]
read more

MAINE PUSHES FORWARD WITH COPAY REFORM

May 6, 2022 | Katie Edmiston

read more

WASHINGTON STATE ENDS LEGISLATIVE SESSION WITH WIN FOR PATIENTS

April 20, 2022 | Katie Edmiston

April 20, 2022 FOR IMMEDIATE RELEASE   STATEMENT FROM NCODA LEGISLATIVE & POLICY ADVISORY COMMITTEE Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org www.ncoda.org WASHINGTON STATE ENDS LEGISLATIVE SESSION WITH WIN FOR PATIENTS The state of Washington wrapped up their legislative session with a huge victory for patients. Senate […]
read more

NCODA and XIFIN Launch New Initiative to Expand Oncology Patient Care Options

April 14, 2022 | Katie Edmiston

NCODA and XIFIN Launch New Initiative to Expand Oncology Patient Care Options “NCODA Informatics Initiative Powered by VisualStrata” Helps Attract Clinical Trials for Oncology Practices and Bridges the Gap with Pharmaceutical Organizations San Diego, CA and Cazenovia, NY April 14, 2022 – XIFIN has partnered with NCODA, Inc., a globally recognized association that develops unique […]
read more

OHIO MAKES IT OFFICIAL: UNANIMOUS VICTORY TO BAN COPAY ACCUMULATORS

April 6, 2022 | Katie Edmiston

FOR IMMEDIATE RELEASE April 6, 2022 STATEMENT FROM NCODA LEGISLATIVE & POLICY ADVISORY COMMITTEE Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison (919) 903-2057 kevin.scorsone@ncoda.org www.ncoda.org OHIO MAKES IT OFFICIAL: UNANIMOUS VICTORY TO BAN COPAY ACCUMULATORS CAZENOVIA, NY – NCODA is proud to share the news that the Ohio House unanimously (86 to 0) […]
read more

NCODA Now Certified To Provide Continuing Education For Pharmacists & Pharmacy Technicians

March 29, 2022 | Katie Edmiston

FOR IMMEDIATE RELEASE  March 29, 2022 MEDIA CONTACT: Katie Edmiston Katie.Edmiston@NCODA.org 813-843-1629   NCODA Now Certified To Provide Continuing Education For Pharmacists & Pharmacy Technicians   CAZENOVIA, NY – NCODA, a professional association dedicated to empowering the medically-integrated oncology community through leadership, quality standards, and best practices, is now certified by the Accreditation Council for […]
read more

Oral Oncolytic Non-Adherence in Medically Integrated Dispensing Pharmacies

March 24, 2022 | Victoria

The challenges associated with medication adherence and the negative impacts of non-adherence have been well documented. Medication adherence affects many aspects of public health, including, but not limited to, quality of life, patient outcomes, and overall healthcare costs.1 It is generally accepted that adherence rates of more than 80% are needed for optimal therapeutic efficacy.2 […]
read more

Oral Oncolytic Care Plans in Medically Integrated Dispensing Pharmacies

March 24, 2022 | Victoria

The development and utilization of oral oncolytics has steadily increased over the past 20 years. There are over 800 new oncology therapies in the drug development pipeline, 25%-35% of which are oral agents.1 The use of oral oncolytics presents unique challenges to patient safety compared to intravenous cancer treatments. As oral oncolytics are self-administered, it […]
read more

First-Of-Its-Kind Oncology State Legislation Tracking Tool

March 15, 2022 | Katie Edmiston

FOR IMMEDIATE RELEASE March 15, 2022 MEDIA CONTACT: Stephen Ziter Stephen.Ziter@ncoda.com 518-867-5001   First-Of-Its-Kind Oncology State Legislation Tracking Tool NCODA Launches a New Comprehensive Resource to Allow Oncology Healthcare Professionals to Stay Updated on the Latest in Relevant Policy/Legislation in all 50 States CAZENOVIA, NY – Today, NCODA announces the launch of its new and […]
read more

CTI BioPharma Announces FDA Accelerated Approval of VONJO™ (pacritinib) for the Treatment of Adult Patients with Myelofibrosis and Thrombocytopenia

March 1, 2022 | Katie Edmiston

– VONJO is the First Approved Therapy to Specifically Address the Needs of Adult Cytopenic Myelofibrosis Patients – NDA Approved Under Priority Review – Approval Triggers $60 Million Payment from DRI Healthcare Trust – CTI to Host Conference Call Tomorrow at 8:00 a.m. ET SEATTLE, Feb. 28, 2022 /PRNewswire/ — CTI BioPharma Corp. (Nasdaq: CTIC) today announced the U.S. […]
read more

Federal Trade Commission Seeking Information on How PBMs Impact Practices and Patients

February 25, 2022 | Katie Edmiston

FOR IMMEDIATE RELEASE   STATEMENT FROM NCODA LEGISLATIVE & POLICY ADVISORY COMMITTEE Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison (919) 903-2057 kevin.scorsone@ncoda.org www.ncoda.org Federal Trade Commission Seeking Information on How PBMs Impact Practices and Patients On February 24, 2022, the Federal Trade Commission (FTC) announced that they are soliciting public input on the […]
read more

PBM REFORM BILL MAKING STRIDES IN VIRGINIA HOUSE OF REPRESENTATIVES

February 25, 2022 | Katie Edmiston

FOR IMMEDIATE RELEASE STATEMENT FROM NCODA’S LEGISLATIVE & POLICY ADVISORY COMMITTEE Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org www.ncoda.org PBM REFORM BILL MAKING STRIDES IN VIRGINIA HOUSE OF REPRESENTATIVES          In recent weeks, NCODA has been closely following and applauding PBM reform along with new provisions regarding patient copayments. […]
read more

OVERWHELMING CONSENSUS IN HOUSE PUTS PBM BILL ON DOORSTEP

February 18, 2022 | Katie Edmiston

February 18, 2022   FOR IMMEDIATE RELEASE   STATEMENT FROM NCODA LEGISLATIVE & POLICY ADVISORY COMMITTEE Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org www.ncoda.org OVERWHELMING CONSENSUS IN HOUSE PUTS PBM BILL ON DOORSTEP A Comprehensive PBM Reform Bill is on the Desk of Michigan Gov. Gretchen Whitmer Awaiting […]
read more

NCODA Stands United With Biden Administration On Cancer Moonshot

February 17, 2022 | Katie Edmiston

Contact: Katie Edmiston | Marketing Manager NCODA, Inc. (813) 843-1629 Katie.Edmiston@ncoda.org   February 17, 2022   NCODA Stands United with Biden Administration on Cancer Moonshot   (CAZENOVIA, NY) – NCODA has always been committed to empowering the medically integrated oncology team to deliver positive, patient-centered outcomes by providing leadership, expertise, quality standards and best practices. […]
read more

Neratinib (Nerlynx®) Diarrhea Management

February 16, 2022 | Victoria

Written by: Eric Dallara, RPh, New England Cancer Specialist Download Here Description:  Diarrhea is the main toxicity of neratinib treatment occurring in 95% of patients in the ExteNET trial on the neratinib arm in which antidiarrheal prophylaxis was not protocol specified.1 Various prevention and treatment strategies for diarrhea have been studied and will be discussed […]
read more

New NDC number for TIBSOVO®

February 15, 2022 | Katie Edmiston

Beginning February 14, 2022, there is a new NDC number for TIBSOVO® (72694-0617-60)*, the old NDC number was 71334-0100-01. SERVIER has new product packaging. The product itself remains the same. Listed below are pictures of the updated product packaging and ordering information. Updated Product Ordering Information: Description Strength/Size Supplier New NDC # TIBSOVO® (ivosidenib tablets) 250 mg tablet […]
read more

Fam-Trastuzumab deruxtecan-nxki (Enhertu®) Management

February 4, 2022 | Victoria

Written by: Brandy Persson, PharmD, BCPS, BCOP and Rebecca Fanning, PharmD, BCPS, Cone Health Download Here Description: Fam-trastuzumab deruxtecan-nxki is indicated for the treatment of: Adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer previously treated with two or more anti-HER2-based regimens.1,2 This indication is under accelerated approval based […]
read more

Durvalumab (Imfinzi®) Therapy Overview

February 4, 2022 | Victoria

Written by: Joshua Nubla, PharmD, NCODA Download Here Description: The purpose of this PQI is to discuss the overall management of durvalumab and immune-mediated adverse events in the treatment of Stage III unresectable NSCLC and first-line extensive stage small cell lung cancer. Background: Durvalumab is a PD-L1 blocking monoclonal antibody and immune checkpoint inhibitor indicated […]
read more

Duvelisib (Copiktra®) for Chronic Lymphocytic Leukemia and Follicular Lymphoma

February 1, 2022 | Victoria

Written by: Linda Frisk, PharmD, Ironwood Cancer and Research Centers Download Here Description: The purpose of this PQI is to provide background on PI3K inhibition and review clinical considerations for duvelisib therapy in order to optimize outcomes for cancer patients as well as identifying the patients with malignant lymphoma who may be candidates for duvelisib. […]
read more